Nuvation Bio Inc. (NUVB)
USD 2.04
(2.78%)
USD 2.04
(2.78%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -75.8 Million USD | 14.51% |
| 2022 | -88.66 Million USD | -11.2% |
| 2021 | -79.73 Million USD | -101.88% |
| 2020 | -39.49 Million USD | -17.72% |
| 2019 | -33.55 Million USD | -3282.26% |
| 2018 | -992 Thousand USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -14.79 Million USD | -7.29% |
| 2024 Q2 | -462.49 Million USD | -3026.64% |
| 2023 Q1 | -16.93 Million USD | -127.41% |
| 2023 Q3 | -19.64 Million USD | 4.8% |
| 2023 Q2 | -20.64 Million USD | -21.91% |
| 2023 FY | -75.8 Million USD | 14.51% |
| 2023 Q4 | -13.78 Million USD | 29.83% |
| 2022 Q2 | -31.84 Million USD | -121.24% |
| 2022 Q1 | -14.39 Million USD | 42.73% |
| 2022 Q3 | -25.06 Million USD | 21.28% |
| 2022 FY | -88.66 Million USD | -11.2% |
| 2022 Q4 | -7.44 Million USD | 70.3% |
| 2021 FY | -79.73 Million USD | -101.88% |
| 2021 Q1 | -20.4 Million USD | -53.63% |
| 2021 Q4 | -25.13 Million USD | -14.35% |
| 2021 Q2 | -19.33 Million USD | 5.24% |
| 2021 Q3 | -21.97 Million USD | -13.69% |
| 2020 Q3 | -11.03 Million USD | -28.32% |
| 2020 Q1 | -8.74 Million USD | 12.64% |
| 2020 FY | -39.49 Million USD | -17.72% |
| 2020 Q4 | -13.28 Million USD | -20.36% |
| 2020 Q2 | -8.59 Million USD | 1.68% |
| 2019 Q1 | -9.31 Million USD | 0.0% |
| 2019 Q4 | -10.01 Million USD | -103.93% |
| 2019 Q3 | -4.9 Million USD | 47.31% |
| 2019 Q2 | -9.31 Million USD | 0.0% |
| 2019 FY | -33.55 Million USD | -3282.26% |
| 2018 FY | -992 Thousand USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| ADC Therapeutics SA | -240.05 Million USD | 68.423% |
| Alto Neuroscience, Inc. | -36.3 Million USD | -108.792% |
| Annovis Bio, Inc. | -56.2 Million USD | -34.869% |
| Biohaven Pharmaceutical Holding Company Ltd. | -408.16 Million USD | 81.429% |
| Ginkgo Bioworks Holdings, Inc. | -892.86 Million USD | 91.51% |
| Nuvation Bio Inc. | -75.8 Million USD | -0.0% |
| Arcus Biosciences, Inc. | -307 Million USD | 75.309% |
| Zymeworks Inc. | -118.67 Million USD | 36.126% |